Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus (Q37778209)

23 August 2017

1 reference

title

Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus (English)

1 reference

23 August 2017

Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus (English)

1 reference

17 June 2024

0 references

1 reference

David Joffe

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20689121

17 June 2024

publication date

1 August 2010

1 reference

23 August 2017

15 August 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20689121

American Journal of Health-System Pharmacy

17 June 2024

published in

1 reference

23 August 2017

volume

67

1 reference

23 August 2017

issue

16

1 reference

23 August 2017

page(s)

1326-1336

1 reference

NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

The Physiology of Glucagon-like Peptide 1

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Investigation of exenatide elimination and its in vivo and in vitro degradation.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Is the reduction of lower-body subcutaneous adipose tissue associated with elevations in risk factors for diabetes and cardiovascular disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Mechanisms of action of glucagon-like peptide 1 in the pancreas

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

When oral agents fail: practical barriers to starting insulin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mell

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

FlexPen: addressing issues of confidence and convenience in insulin delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for th

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090230

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

31 March 2020

series ordinal

45

1 reference

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension

17 June 2024

series ordinal

54

1 reference

Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension

17 June 2024

series ordinal

55

1 reference

17 June 2024

Identifiers

DOI

10.2146/AJHP090230

1 reference

23 August 2017

1 reference